Literature DB >> 26792477

Tuberculosis treatment outcomes among peri-urban children receiving doorstep tuberculosis care.

L Jeena1, K Naidoo2.   

Abstract

OBJECTIVE: To determine the optimal tuberculosis (TB) management strategy for children living in peri-urban, resource-limited settings.
DESIGN: We compared TB treatment outcomes among children aged 0-15 years receiving doorstep care (n = 82) with those of a historical group (n = 97) receiving clinic-based care.
RESULTS: The doorstep care and clinic-based groups had similar age and sex profiles; treatment default rates were 3.7% (3/82) vs. 38.1% (37/97, P < 0.0001), treatment completion rates were 65.9% (54/82) vs. 51.6% (50/97, P = 0.01), and cure rates were 13.4% (11/82) vs. 2.1% (2/97), respectively (P < 0.0001).
CONCLUSION: Children living in peri-urban communities had improved TB treatment outcomes with doorstep care.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26792477      PMCID: PMC4989031          DOI: 10.5588/ijtld.15.0090

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  10 in total

1.  Estimates of tuberculosis progression rate of children in China.

Authors:  Hui Cao; Yicang Zhou; Fred Brauer
Journal:  J Biol Dyn       Date:  2012       Impact factor: 2.179

2.  Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes.

Authors:  A D Harries; N J Hargreaves; S M Graham; C Mwansambo; P Kazembe; R L Broadhead; D Maher; F M Salaniponi
Journal:  Int J Tuberc Lung Dis       Date:  2002-05       Impact factor: 2.373

3.  Reported childhood tuberculosis treatment outcomes, Gaborone and Francistown, Botswana, 1998-2002.

Authors:  J E Oeltmann; B Chengeta; J J Mboya; C D Wells; P H Kilmarx; T Samandari; L J Nelson
Journal:  Int J Tuberc Lung Dis       Date:  2008-02       Impact factor: 2.373

4.  Profile and outcome of childhood tuberculosis treated with DOTS--an observational study.

Authors:  Pushpa Panigatti; Vinod Hanumant Ratageri; Illalu Shivanand; P K Madhu; T A Shepur
Journal:  Indian J Pediatr       Date:  2013-07-28       Impact factor: 1.967

Review 5.  Directly observed therapy for treating tuberculosis.

Authors:  J Volmink; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 6.  Diagnostic and management challenges for childhood tuberculosis in the era of HIV.

Authors:  B J Marais; S M Graham; M F Cotton; N Beyers
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

Review 7.  Paediatric tuberculosis.

Authors:  Sandra M Newton; Andrew J Brent; Suzanne Anderson; Elizabeth Whittaker; Beate Kampmann
Journal:  Lancet Infect Dis       Date:  2008-08       Impact factor: 25.071

8.  Seven-year DOTS-Plus pilot experience in India: results, constraints and issues.

Authors:  R Singla; R Sarin; U K Khalid; K Mathuria; N Singla; A Jaiswal; M M Puri; P Visalakshi; D Behera
Journal:  Int J Tuberc Lung Dis       Date:  2009-08       Impact factor: 2.373

9.  Childhood tuberculosis and its treatment outcomes in Addis Ababa: a 5-years retrospective study.

Authors:  Dereje Hailu; Woldaregay Erku Abegaz; Mulugeta Belay
Journal:  BMC Pediatr       Date:  2014-03-03       Impact factor: 2.125

Review 10.  Epidemiology and disease burden of tuberculosis in children: a global perspective.

Authors:  James A Seddon; Delane Shingadia
Journal:  Infect Drug Resist       Date:  2014-06-18       Impact factor: 4.003

  10 in total
  2 in total

1.  Outcomes in children treated for tuberculosis with the new dispersible fixed-dose combinations in Port Moresby.

Authors:  V Apis; M Landi; S M Graham; T Islam; J Amini; G Sabumi; A M Mandalakas; T Meae; P du Cros; H D Shewade; H Welch
Journal:  Public Health Action       Date:  2019-09-21

2.  Test and Treat TB: a pilot trial of GeneXpert MTB/RIF screening on a mobile HIV testing unit in South Africa.

Authors:  Ingrid V Bassett; Leah S Forman; Sabina Govere; Hilary Thulare; Simone C Frank; Bright Mhlongo; Elena Losina
Journal:  BMC Infect Dis       Date:  2019-02-04       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.